BRD4 and acute myeloid leukemia: By selectively suppressing the BD2 bromodomain, ABBV-744 induces acute myeloid leukemia and prostate cancer cell growth inhibition, and exhibits significant anticancer effects against acute myeloid leukemia and prostate cancer in mouse models with better toxicity profile and therapeutic index than BRD4 BD1 and BD2 bromodomain inhibitors [55, 56].